Novartis Gleevec
Executive Summary
Express Scripts will be the exclusive provider for the Gleevec patient assistance program. Imatinib mesylate was approved May 10 for chronic myeloid leukemia and is expected to cost up to $30,000 a year (1"The Pink Sheet" May 14, p. 4)